RxDoctor Payments Data

Anand Patel, MD

Emergency Medicine · San Diego, CANPI 1225070345

Payments from drug & device makers

$15,149in general payments, 2019–2025

Across 10 payments — averaging $1514.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mediview XR, Inc.$15K
  • Johnson & Johnson$149

What the payments were for

  • Consulting fees$15,00099%
  • Food & beverage$1491%

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mediview XR, Inc.2$15,000
Johnson & Johnson8$149

How this compares

$15,149 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.

See all emergency medicine providers in California

Medicare billing

Part B allowed, 2024
$427,229
Medicare patients
539
Services billed
4,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$224,172
XareltoRivaroxaban91$62,540
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,442
OzempicSemaglutide34$46,116
TrulicityDulaglutide30$44,160
XifaxanRifaximin13$43,749
MyrbetriqMirabegron99$34,536
CreonLipase/Protease/Amylase20$29,080
JanuviaSitagliptin Phosphate36$28,716
Invega SustennaPaliperidone Palmitate12$26,705
JardianceEmpagliflozin28$26,508
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,101
EntrestoSacubitril/Valsartan23$15,540
RytaryCarbidopa/Levodopa18$13,248
HorizantGabapentin Enacarbil26$12,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna$149$89,244103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,006 emergency medicine providers in California.

Other emergency medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →